Table of Contents
Study F1K-MC-EVAD: Relative Risk under Original and Amended Protocols
Study F1K-MC-EVAD: Relative Risk by Site Enrollment
Study F1K-MC-EVAD: Mortality by Type of Clinical Trial Material
Study F1K-MC-EVAD: Cox Regression Analysis by Baseline and Any Heparin Exposure Placebo Patients
Study F1K-MC-EVAD: Patient Populations within First APACHE II Quartile – IL-6 Level
Study F1K-MC-EVAD: Location and Functional Status – Original vs Amended Protocol
Study F1K-MC-EVAD: Safeguards to Maintain Study Blind during Conduct of Interim Analyses
Study F1K-MC-EVAD: Mortality by Adequate Use of Antibiotics (CEC)
Study F1K-MC-EVAD: Mortality by Culture or Blood Culture (CEC)
Study F1K-MC-EVAD: Stepwise Multiple Logistic Regression
Study F1K-MC-EVAD: Stepwise Multiple Logistic Regression
PPT Slide
Study F1K-MC-EVAD: Stepwise Multiple Logistic Regression Results
Study F1K-MC-EVAD: Data Safety Monitoring Board Members
Study F1K-MC-EVAD: Cumulative Mortality
Study F1K-MC-EVAD: Cumulative Mortality Sites Enrolling under Original and Amended Protocols
Why not a randomized controlled trial in kids?
Controlled Trial Sample Size Estimates
Studies F1K-MC-EVAO/EVAD: Number of Organ Failures at Baseline – Pediatric versus Adult Patients
Studies F1K-MC-EVAO/EVAD: Type of Organ Failure at Baseline – Pediatric versus Adult Patients
Studies F1K-MC-EVAO/EVAD: Percent of Patients with Positive Cultures at Baseline
Reporting of Adverse Events – Study F1K-MC-EVAO versus Study F1K-MC-EVAD
Study F1K-MC-EVAO: Adverse Events Occurring in ?5% of Patients – Part 2
Study F1K-MC-EVAO: Baseline Organ Failures for Selected Safety Categories
Study F1K-MC-EVAO: Intracerebral Hemorrhage – Patient Scenario 1
Study F1K-MC-EVAD: Location Prior to Hospitalization – First APACHE II Quartile
|